Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Pipeline Review, H1 2019
Summary
Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 Pipeline Review, H1 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNFreceptor superfamily. This receptor has been shown to activate NFkappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on Tcells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 5 and 8 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Gastrointestinal, Immunology and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, NonSmall Cell Lung Cancer, Cervical Cancer, Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Lung Cancer, Metastatic Melanoma, Renal Cell Carcinoma, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Atopic Dermatitis Atopic Eczema, BCell NonHodgkin Lymphoma, Colon Cancer, Diffuse Large BCell Lymphoma, Endometrial Cancer, Esophageal Cancer, Follicular Lymphoma, Hepatitis B, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Hypopharyngeal Cancer, Kidney Cancer Renal Cell Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional Urothelial Tract Cancer, MethicillinResistant Staphylococcus aureus MRSA Infections, Ocular Melanoma, Oral Cavity Mouth Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous NonSmall Cell Lung Cancer, Transplant Rejection, Type 1 Diabetes Juvenile Diabetes, Ulcerative Colitis and Uterine Cancer.
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope